Get started
AstraZeneca PLC Sponsored ADRAstraZeneca PLC Sponsored ADRAstraZeneca PLC Sponsored ADR

AstraZeneca PLC Sponsored ADR

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsTechnicalsForecastSeasonalsOptionsBondsETFs

AZN chart


Full chart

Key facts today


AstraZeneca's Enhertu demonstrated significant improvement in invasive disease-free survival over T-DM1 in the DESTINY-Breast05 Phase III trial for high-risk early breast cancer patients.
AstraZeneca's stock closed at 1,403.50 SEK, marking an increase of 11.50 SEK or 0.83% in the latest trading session.
AstraZeneca has created antibody drugs to prevent respiratory syncytial virus (RSV) in children, highlighting the lack of U.S.-approved treatments for RSV in adults.
Analyze the impactAnalyze the impact

AZN upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪228.49 B‬ USD
Dividend yield (indicated)
2.08%
Price to earnings Ratio (TTM)
27.58
Basic EPS (TTM)
2.68 USD
Net income (FY)
‪7.04 B‬ USD
Revenue (FY)
‪54.10 B‬ USD
Shares float
‪3.10 B‬
Beta (1Y)
0.22

About AstraZeneca PLC


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Pascal Soriot
Website
astrazeneca.com
Headquarters
Cambridge
Founded
1913
ISIN
US0463531089
FIGI
BBG000BZ0DK8
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed. AstraZeneca was founded in 1999 through the merger of Astra AB and Zeneca Group PLC. The company is headquartered in Cambridge, the United Kingdom.

Check out other big names from the same industry as AZN.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

AZN news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

AZN highest yielding bonds


US46353AZ1
AstraZeneca PLC 3.0% 28-MAY-2051
Yield to maturity
5.27%
Maturity date
May 28, 2051
US46353AU2
AstraZeneca PLC 4.375% 17-AUG-2048
Yield to maturity
5.26%
Maturity date
Aug 17, 2048
US46353AM0
AstraZeneca PLC 4.375% 16-NOV-2045
Yield to maturity
5.26%
Maturity date
Nov 16, 2045
US46353AX6
AstraZeneca PLC 2.125% 06-AUG-2050
Yield to maturity
5.24%
Maturity date
Aug 6, 2050
AZN3901525
AstraZeneca PLC 4.0% 18-SEP-2042
Yield to maturity
5.18%
Maturity date
Sep 18, 2042
US46353AL2
AstraZeneca PLC 3.375% 16-NOV-2025
Yield to maturity
5.12%
Maturity date
Nov 16, 2025
AZN.GE
AstraZeneca PLC 6.45% 15-SEP-2037
Yield to maturity
4.85%
Maturity date
Sep 15, 2037
A
US4636NAN3
AstraZeneca Finance LLC 5.0% 26-FEB-2034
Yield to maturity
4.57%
Maturity date
Feb 26, 2034
50UC
AstraZeneca PLC 5.75% 13-NOV-2031
Yield to maturity
4.47%
Maturity date
Nov 13, 2031
A
AZN5549116
AstraZeneca Finance LLC 4.875% 03-MAR-2033
Yield to maturity
4.38%
Maturity date
Mar 3, 2033
A
US4636NAA1
AstraZeneca Finance LLC 1.2% 28-MAY-2026
Yield to maturity
4.30%
Maturity date
May 28, 2026

See all AZN bonds 

Sparks


Curated watchlists where AZN is featured.

See all sparks